Manhattan Scientifics and Dr. Edward Flynn featured in article on Novel Early Cancer Detection and Treatment
February 4, 2010
ALBUQUERQUE, NM February 4, 2010 --- Manhattan Scientifics (OTC BB: MHTX) is pleased to post an article from the New Mexico Business Weekly describing the early cancer detection work of Dr. Edward R. Flynn.
Read the article on the Manhattan Scientifics' website by linking to http://www.mhtx.com/dr-edward-flynn.htm
The article describes how “Flynn is drawing on his experience as a nuclear physicist to develop new, ground-breaking technology that can detect breast and ovarian cancers much earlier than current diagnostic techniques. His work also has produced an innovative method to more accurately determine if leukemia patients are benefiting from chemotherapy treatments. Flynn’s technology is based on magnetic nano particles injected into the body. The particles carry antibodies that bind with cancer cells to pinpoint the exact location of diseases, both for diagnostics and for targeted therapies.”
Dr. Flynn’s research has been funded by Small Business Innovative Research Grants from the National Institutes of Health. Senior Scientific collaborates with the University of New Mexico Health Sciences Center. Dr. Flynn state, “I am confident that by partnering with Manhattan Scientifics now, our team will achieve the ultimate goals of the program.”
On October 20, 2009, Manhattan Scientifics and Dr. Flynn signed an initial Letter of Intent describing their intention to cooperate to commercializing products and technologies arising out of Dr. Flynn's work. The parties are finalizing a definitive agreement to move forward together.
Manhattan Scientifics, Inc., www.mhtx.com, operates with locations in New Mexico, New York, and Montreal. The company’s goal is to advance and commercialize disruptive technologies to create profit for its shareholders. It is focused on the commercialization of disruptive technologies in the nanotechnology field.
This press release contains projections of future results and other forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Important factors that may cause actual results and outcomes to differ materially from those contained in the projections and forward-looking statements included in this press release are described in our publicly filed reports. Factors that could cause these differences include, but are not limited to, failure to realize projected revenues and cash flows and market conditions that negatively affect the market for our technology. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
- Contacts:
Investor Relations Contact:
Premier Media Service Inc.
Kelly Black or Heather Mund, 480-649-8224
kblack@premiermediaservice.com
hmund@premierfundingservice.com
or
Executive Contacts:
Manhattan Scientifics, Inc.
Manny Tsoupanarias, Chief Executive Officer
918-919-0370
mtsoupanarias@manhattan-scientifics.com
or
Manhattan Scientifics, Inc.
Marvin Maslow, Director of Investor Relations, 917-923-3300
Marvin@MarvinMaslow.com
or
European Investor Relations:
IR-Unternehmensberatungs GmbH
Herbert Strauss, +43 316 296 316
herbert@eu-ir.com
or
Institutional Investor Relations:
Premier Media Service Inc.
Kelly Black or Heather Mund, 480-649-8224
kblack@premiermediaservice.com
hmund@premierfundingservice.com
Manhattan Scientifics Inc. © 2008 | Disclaimer
